Abstract
The COVID-19 pandemic has posed a big challenge to the healthcare community and many stakeholders. According to clinical studies, D-Dimer assays may be the "first line" of technical screening in symptomatic outpatients with suspected venous thrombosis or pulmonary embolism. This same affirmation may be applied to COVID-19 as its cause. In this study the comparison of the first two years of the COVID-19 appears the tendency of treatment decision making based in D-Dimer levels being a less important parameter. Many patients with COVID-19 have been observed to present with prominently elevated D-Dimers, findings which have been postulated to reflect underlying thromboembolic burden, which have been associated with increased mortality among such patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Family & Community Medicine
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
